Insulin-like growth factor 1 (IGF1) and its main binding protein, IGF-binding protein 3 (IGFBP3), play an important role in cancer development. Circulating levels and functional polymorphisms of IGF1 and IGFBP3 may be biomarkers of cancer development. However, the results of published studies remain conflicting rather than conclusive. We searched MEDLINE and EMBASE databases for all published studies related to circulating levels and polymorphisms of IGF1 and IGFBP3 and cancer risk. In all, 96 studies and over 110 000 subjects were available for this meta-analysis. Higher IGF1 circulating levels significantly increased 15% of cancer risk (odds ratio (OR), 1.15, 95% confidence interval (CI), 1.03-1.29), especially among prostate, pre-menopausal breast and colorectal cancer patients, whereas higher concentrations of IGFBP3 significantly decreased the risk of advanced prostate cancer by 56% (OR, 0.44, 95% CI, 0.25 -0.77). Meanwhile, IGFBP3 À202CC genotype was associated with an increased risk of prostate cancer with borderline significance (OR, 1.18, 95% CI, 0.99 -1.41). Genotype-phenotype correlation analyses showed that circulating levels of IGFBP3 could be modified by its promoter polymorphism AÀ202C (P o 0.001). In conclusion, circulating levels of IGF1, IGFBP3 and IGFBP3 AÀ202C play a crucial role in carcinogenesis and could serve as susceptibility biomarkers for cancer development.
Introduction
Insulin-like growth factor-1 (IGF1) is an important regulator of cellular proliferation, differentiation and apoptosis. 1 More than 90% of the circulating IGF1 is bound to insulin-like growth factor-binding protein-3 (IGFBP3), which regulates the biological activity of IGF1. It was reported that there was a great interindividual variation in serum levels of IGF1 and IGFBP3 2 and several epidemiological observations showed that circulating levels of IGF1, IGFBP3 and their molar ratio were associated with risk of common cancers. 3 -5 Twin studies suggested a genetic basis accounting for nearly 60% of the interindividual variability of circulating levels of IGF1 and IGFBP3. 6 Several genetic polymorphisms were identified to influence the circulating levels of IGF1 and IGFBP3. For example, the number of (CA)n dinucleotide repeat at 1 kb upstream from the transcription start site of IGF1 was found to be inversely correlated with the transcription activity of IGF1. 7, 8 Meanwhile, two genetic variants were reported to link to IGFBP3 levels. 9 -11 One is a promoter single nucleotide polymorphism (SNP) located at position À202 (rs2854744, A4C) from the transcription start site of IGFBP3, 9 resulting in a reduced promoter activity and decreased IGFBP3 levels. 9, 10 The other one is a non-synonymous substitution, Gly32Ala (rs2854746, G4C), and the presence of the variant 32Ala allele was inversely associated with IGFBP3 levels. 11 Recently, molecular epidemiological studies showed that these SNPs, such as IGF1 (CA)n, IGFBP3 AÀ202C and Gly32Ala, were associated with susceptibility of diverse cancers, including breast 12 -14 prostate, 15 colorectal 16 and gastric cancers. 17 However, the results were controversial rather than conclusive. 18, 19 To estimate the effect of phenotypes (circulating levels) and genotypes (functional SNPs) of IGF1 and IGFBP3 associated with the risk of multiple cancer sites as well as individual cancers, we conducted a systematic meta-analysis with 96 published studies.
Subjects and methods

Identification and eligibility of studies
We included all the studies with epidemiological study designs of case -control, cohort, or cross-sectional studies, published to date on the associations of phenotypes (circulating concentrations) and genotypes (SNPs) of IGF1 and IGFBP3 with cancer risk. Eligible studies were identified by searching the electronic literatures (MEDLINE and EMBASE) for relevant reports (last search date on April 30, 2008, using the search terms 'IGF* and cancer' and 'IGF* polymorphisms and cancer') by two independent investigators (W Chen and S Wang). Additional studies were identified by a hand search of references of original studies or review articles on this topic. 3,4,18 -22 All the available studies should describe their data with ORs and 95% CIs, and have at least three categories (for example, tertiles to quintiles) of IGF1 and IGFBP3 levels. If studies had partly overlapped subjects, only the one with a larger sample size was selected. The two investigators (W Chen and S Wang) reached coherence on all the selected studies included in the final analyses. As a result, 96 published studies were eligible for further analyses. Sixty-five studies were available for phenotype analysis (63 for IGF1, 60 for IGFBP3 and 21 for IGF1/ IGFBP3 molar ratio), including 15 212 cases and 27 913 controls. Pre-and post-menopausal breast cancers were evaluated separately. For IGF1, two studies had only stratified information by age or sex, so we divided them into two substudies. 23, 24 Twenty-seven studies investigated the potential functional polymorphisms (19 for IGF1 (CA) n , 16 for IGFBP3 AÀ202C and 6 for IGFBP3 Gly32Ala), including 27 852 cases and 40 354 controls. One multicenter study 14 was included and two duplicated articles were excluded for the association between genotypes and cancer risk. 25, 26 Nine studies were available for genotypephenotype correlation analysis.
Data extraction
All the selected studies presented their main findings with ORs and 95% CIs in terms of phenotypes (levels of IGF1, IGFBP3 or IGF1/IGFBP3 molar ratio) and cancer risk. Genotype frequencies were collected to pool the polymorphism data. In the genotype -phenotype correlation analysis, to avoid the influence of IGF1 or IGFBP3 levels from therapeutic effects, we only analyzed the relevant information in healthy controls. Different ethnicities were categorized as Asian, African and Caucasian. Subjects without exact ethnic information were classified as the mixed ethnic subgroup (Supplementary Tables 1  and 2 ). Test of heterogeneity and publication bias DerSimonian and Laird Q test was used to assess the degree of heterogeneity between studies and the heterogeneity was considered significant when Po0.05. 29 When the betweenstudy heterogeneity was found, a random-effect model was conducted. Sources of heterogeneity were determined by using random-effect meta-regression models with restricted maximum likelihood estimation. The inter-study variance (t 2 ) was used to quantify the degree of heterogeneity between studies and the percentage of t 2 was used to describe the extent of explained heterogeneity. 30 Publication bias was evaluated by the linear regression asymmetry test by Egger et al 31 All data were analyzed in Statistical Analysis System software (v.9.1.3; SAS Institute, Cary, NC, USA), STATA7.0 (Stata-Corp, College Station, TX, USA) and Review Manager (v.4.2; Oxford, England). All P-values were based on two-sided tests and a P-value of less than 0.05 was considered statistically significant.
Statistical analysis
Results
Phenotypes and cancer risk
Sixty-five studies were included to assess the associations of IGF1 and IGFBP3 levels with cancer risk. Among them, there were 21 studies for prostate cancer, 11 for premenopausal breast cancer, 9 for post-menopausal breast cancer, 10 for colorectal cancer, 5 for lung cancer, 5 for endometrial cancer, 4 for ovarian cancer, 3 for pancreatic cancer and 5 for other tumors (Supplementary Table 1 Figure 1 ). Twenty-one studies (4603 cases and 9165 controls) detected circulating levels of both IGF1 and IGFBP3, and evaluated the associations between their molar ratio and cancer risk. We found that higher IGF1/IGFBP3 molar ratio could increase colorectal cancer risk with borderline significance (OR, 1.70; 95% CI, 0.98 -2.96). Figure 1 ). However, À202C significantly contributed to breast cancer risk in the dominant genetic model (OR, 1.07; 95% CI, 1.01 -1.13). Figure 1 Circulating concentrations of IGF1 or IGFBP3 relation to prostate cancer risks.
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We also observed that À202C allele was associated with a 13% increased risk of prostate cancer in the recessive model (OR, 1.13; 95% CI, 0.97 -1.31). However, the effect was not statistically significant (P ¼ 0.110). For IGFBP3 Gly32Ala, no significant associations were found (Table 3) .
Genotype -phenotype correlation
The two promoter polymorphisms, IGF (CA) n and IGFBP3 AÀ202C, were suggested to be associated with transcription activity of their target genes. 32, 33 To further evaluate the genotype-phenotype correlations, we conducted the analyses between these genetic variants and circulating levels of IGF1 and IGFBP3 in healthy controls. Five studies were available for the analysis between IGF1 (CA) n polymorphism and IGF1 levels, 11,34 -37 but no significant correlation was found ( Figure 2 ).
Test of heterogeneity and publication bias
We evaluated the sources of heterogeneity in relation to cancer site, study design and ethnicity. We found that the cancer site could explain substantial altered heterogeneity among studies focusing on phenotypes and cancer risk (55. Egger's test was used to detect the potential publication bias, which was more pronounced when the higher intercept deviated from zero in linear regression analysis. We did not find significant publication bias for circulating levels of IGF1 and IGF1/IGFBP3 molar ratio (P-value, 0.522 and 0.531, respectively), polymorphisms of IGFBP3 AÀ202C and Gly32Ala (P-value, 0.106 and 0.805, respectively). However, for circulating levels of IGFBP3 and IGF1 (CA) n polymorphism, publication bias was significant (P all o0.001).
Discussion
In this meta-analysis, we systematically investigated the relationship between IGF1 or IGFBP3 genotypes and phenotypes and cancer risk. We found that higher circulating concentrations of IGF1 were significantly IGF1, IGFBP3 and cancer susceptibility W Chen et al associated with increased risk of all cancers combined, especially in cancers of pre-menopausal breast, colorectal and prostate. In addition, higher circulating levels of IGFBP3 significantly decreased risk of advanced prostate cancer. Meanwhile, IGFBP3 promoter polymorphism, AÀ202C, was associated with an increased prostate cancer risk and modified the circulating levels of IGFBP3. IGF1 and IGFBP3 has an important role in tumor development. 3, 4 From the present pooled analyses, we found that higher concentrations of IGF1 were significantly associated with an increased risk of pre-menopausal breast cancer but not of post-menopausal breast cancer, which was consistent with previously published studies. 4, 39, 40 It was reported that estrogen could interact with IGF1 to increase cell proliferation, particularly in breast cancer cells. 41 In addition, both estrogen 42 and IGF1 levels were higher in pre-menopausal breast cancer than those in post-menopausal breast cancer, suggesting that IGF1 might have a different role in pre-and postmenopausal breast cancers. We also found that higher circulating levels of IGFBP3 were significantly associated with altered risk of pre-menopausal breast cancer, which was consistent with Renehan's conclusion. 4 It was reported that IGFBP3 could play an anti-apoptotic role in Hs578T breast cancer cells. 43 Besides, body size, vigorous physical activity, and dietary factors could influence IGF1 and IGFBP3 molar ratio in pre-menopausal breast cancer women more than postmenopausal breast cancer women, 44 and they might account for the different roles of IGF1 and IGFBP3 in breast cancer according to menopausal status. IGF1 could also modulate androgen receptor (AR) activity by PI3K/Akt or Ras/MAPK pathway, leading to AR phosphorylation and sensitization to low concentrations of androgens, 45 suggesting that IGF1 might play a crucial role in prostate cancer. It was reported that IGF1 could induce ligand-independent activation of AR and enhance the expression of matrix metalloproteinase-2. 46 In this meta-analysis, the effects of circulating levels of IGF1, IGFBP3 and IGFBP3 AÀ202C polymorphism were more Apart from cancer site, other factors might also account for heterogeneity across studies, such as ethnicity and study design. Study design and ethnicity contribute much to the heterogeneity for the association between circulating levels of IGF1 and cancer risk. The results of population-based case -control studies were comparable with those of nested case -control studies, but were different from those of hospital-based case -control studies. It is possible that hospital-based case -control studies might suffer from selection bias of study subjects. As for ethnicity, however, only two studies and limited number of patients were available for Africans, which limited us to detect stable effects in this population, and more populationbased or prospective studies are needed.
As a meta-analysis of observational studies, our results have some potential limitations. Firstly, this type of metaanalysis is vulnerable to biases inherent in the original studies. 4 Secondly, further analysis for some important confounding factors such as body mass index and physical activity were neglected because of limited information from original studies, although these two factors might influence the concentrations of IGF1 or IGFBP3. Further larger studies with both genotypes and phenotypes of IGF1and IGFBP3 with functional evaluations, and geneenvironmental interactions on the risk of different cancers are warranted.
